Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo by Lee, Seung Joon et al.
RESEARCH ARTICLE Open Access
Curcumin-induced HDAC inhibition and
attenuation of medulloblastoma growth in vitro
and in vivo
Seung Joon Lee
1, Candice Krauthauser
1, Victoria Maduskuie
2, Paul T Fawcett
2, James M Olson
3 and
Sigrid A Rajasekaran
1*
Abstract
Background: Medulloblastoma is the most common brain tumor in children, and its prognosis is worse than for
many other common pediatric cancers. Survivors undergoing treatment suffer from serious therapy-related side
effects. Thus, it is imperative to identify safer, effective treatments for medulloblastoma. In this study we evaluated
the anti-cancer potential of curcumin in medulloblastoma by testing its ability to induce apoptosis and inhibit
tumor growth in vitro and in vivo using established medulloblastoma models.
Methods: Using cultured medulloblastoma cells, tumor xenografts, and the Smo/Smo transgenic medulloblastoma
mouse model, the antitumor effects of curcumin were tested in vitro and in vivo.
Results: Curcumin induced apoptosis and cell cycle arrest at the G2/M phase in medulloblastoma cells. These
effects were accompanied by reduced histone deacetylase (HDAC) 4 expression and activity and increased tubulin
acetylation, ultimately leading to mitotic catastrophe. In in vivo medulloblastoma xenografts, curcumin reduced
tumor growth and significantly increased survival in the Smo/Smo transgenic medulloblastoma mouse model.
Conclusions: The in vitro and in vivo data suggest that curcumin has the potential to be developed as a
therapeutic agent for medulloblastoma.
Background
Brain tumors are the second most frequent malignant
tumors in children and are generally associated with a
worse prognosis when compared with other common
pediatric cancers [1]. Among pediatric brain tumors,
medulloblastoma is the most common malignant form
[2]. Despite recent improvements in survival rates,
medulloblastoma is incurable in about a third of
patients, and survivors undergoing current treatment
suffer from serious therapy-related side-effects [3]. Most
medulloblastomas are thought to originate from cerebel-
lar granule neuron precursors (CGNPs) [4], and several
signaling pathways have been implicated in medulloblas-
toma formation including aberrant activation of WNT,
sonic hedgehog (Shh), and epidermal growth factor
receptor (EGFR) signaling cascades. Consequently, sev-
eral therapeutic strategies, such as monoclonal antibo-
dies and small molecule inhibitors, have been employed
to target these pathways and succeeded in eradicating
spontaneous medulloblastoma in transgenic and trans-
plantation mouse models [5]. However, while these
agents might have limited to no side effects in adults, in
juvenile mice, even transient exposures to a Shh path-
way inhibitor resulted in permanent defects in bone
development [6], impeding the therapeutic potential
against pediatric cancers. Thus, it remains a challenge to
identify safe and effective treatment options for pediatric
brain tumors, such as medulloblastoma.
Curcumin, also known as diferuloylmethane, is a
major component of the spice turmeric derived from
the plant Curcuma longa. It has been used widely in
India and other parts of Southeast Asia as a spice and a
medicine with anti-inflammatory and anti-oxidant prop-
erties. Recently, curcumin has been highlighted as a
* Correspondence: sraj@medsci.udel.edu
1Nemours Center for Childhood Cancer Research, Alfred I. duPont Hospital
for Children, 1701 Rockland Road, Wilmington, DE 19803, USA
Full list of author information is available at the end of the article
Lee et al. BMC Cancer 2011, 11:144
http://www.biomedcentral.com/1471-2407/11/144
© 2011 Lee et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.potent anti-cancer agent, with chemopreventive and
chemotherapeutic potential with no discernible side
effects. Curcumin inhibits the proliferation of diverse
tumor cells in culture, prevents carcinogen-induced can-
cers in mouse models, and impedes the tumor growth
in various xenotransplant and orthotransplant mouse
models [7,8]. Therapeutic efficacy of curcumin by itself
or in combination with other drugs is in phase I/II clini-
cal trials against several adulthood tumors such as color-
ectal, liver, pancreatic, and prostate cancer and against
multiple myeloma [7,8]. The possible chemotherapeutic
effects of curcumin are now being well-accepted in
adulthood cancers. Curcumin has been used safely as a
dietary component for centuries and, thus, may prove to
be a potentially safer drug alternative in pediatric
cancers.
Most importantly, curcumin has the ability to cross
the blood-brain barrier (BBB) [7,9-11]. BBB is a specia-
lized system of brain microvascular endothelial cells that
separates the central nervous system from the peripheral
blood and serves to supply brain tissue with nutrients,
to protect the neuroparenchymal microenvironment,
and to shield the brain from potentially toxic substances
in the blood, including therapeutic drugs. Consequently,
the failure of treatment in many instances is not due to
an intrinsic lack of potency of the drugs, but instead
due to the BBB, which impedes efficient drug delivery
[12,13]. Since curcumin can cross the BBB [7,9-11], it
may thus prove effective for chemotherapy for pediatric
brain tumors.
Epigenetic modifications including acetylation of his-
tones and non-histone proteins play a central role in the
development of human cancers [14,15]. The acetylation
status of proteins is determined by histone deacetylases
(HDACs) and histone acetyltransferases (HATs) that
remove and add acetyl groups to lysine residues, respec-
tively. By removing acetyl groups from histones, leading
to chromatin condensation, HDACs can act as tran-
scription repressors that selectively alter gene transcrip-
tion. In addition, HDACs have many non-histone
protein substrates such as transcription factors, hor-
mone receptors, signaling mediators, chaperones, and
cytoskeletal proteins, which regulate cell proliferation
and cell death [16,17]. At present, 18 HDAC isoforms
are known and classified into four groups based on their
structural homology: the classical Zn
2+-dependent class
I, class IIa, class IIb HDACs and the NAD
+ dependent
sirtuins (class III), and HDAC11 (class IV) [18]. The
ubiquitously expressed class I HDACs are the best-char-
acterized of these proteins. With their primarily nuclear
localization, they are crucial for transcriptional repres-
sion and epigenetic landscaping. Class II HDAC family
members have a more tissue-specific expression pattern,
and class IIa members are primarily expressed in heart,
smooth muscle, and brain. HDACs are considered pro-
mising targets in drug development for cancer therapy
[19-21]. HDAC inhibitors can cause cell cycle arrest and
induce growth arrest, differentiation, or apoptosis in
vitro and in vivo. The first clinical trials have shown
their potential as therapeutics for hematological and
solid epithelial tumors in adult patients [22]. In neuronal
cells, HDAC inhibitors have yielded conflicting results.
For example, HDAC inhibition blocks neuronal loss in a
mouse model of Huntington’s disease and in Drosophila,
suggesting that HDAC inhibitors are neuro-protective
[23-25]. In cerebellar granule neurons, pharmacological
inhibition of HDACs induced apoptosis [26-29], suggest-
ing that individual HDAC members may have distinct
and sometimes opposing roles, given the cellular context
[30].
Curcumin interacts with a wide variety of proteins to
modify their expression and activity, ultimately inhibit-
ing cell proliferation, invasion, angiogenesis, and metas-
t a s i so fd i f f e r e n tt y p e so fc a n c e r s .W h i l et h ep r i m a r y
molecular targets and mechanisms of curcumin action
remain to be determined, curcumin has been shown to
induce apoptosis in a wide variety of cell lines and inhi-
bits tumor growth in in vivo models of various cancers
[7,8]. We found that curcumin induces cell cycle arrest
and elicits apoptosis in medulloblastoma cells. Inhibition
of cell cycle progression by curcumin was accompanied
by altered organization of mitotic spindle microtubules,
probably due to increased tubulin acetylation. Consistent
with increased tubulin acetylation, curcumin inhibited
HDAC activity and repressed HDAC4 expression in
medulloblastoma cells. Although curcumin-induced cell
death in medulloblastoma cells has been reported in
earlier studies [31,32], we show for the first time that
curcumin reduces tumor growth in medulloblastoma
xenografts and increases survival in the Smo/Smo trans-
genic mouse model of medulloblastoma. Thus, curcu-
min may be a useful for children with medulloblastoma.
Methods
Cell lines and reagents
The human medulloblastoma cell lines DAOY, D283
Med, and D341 Med were obtained from the American
Type Culture Collection (ATCC, Manassas, VA) and
cultured in MEM supplemented with 10% (DAOY,
D283 Med) or 20% (D341 Med) fetal bovine serum, glu-
tamine and penicillin/streptomycin in a humidified, 5%
CO2 atmosphere at 37°C. The DAOY cell line stably
expressing tdTomato was generated by transfecting
ptdTomato-N1 (Clontech, CA) into DAOY cells fol-
lowed by selection with 500 μg/ml of G418 for 2 weeks.
Cells were then diluted serially for clonal isolation and
ptdTomato positive clones were used for xenograft
studies.
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were purchased from Sigma-Aldrich (St. Loius, MO).
Antibodies against acetylated tubulin, cleaved Caspase3,
cleaved PARP, GAPDH, NFB, HDAC2, HDAC4,
HDAC5, HDAC7, phospho-HDAC4 (S246)/HDAC5
(S259)/HDAC7 (S155), and horseradish peroxidase
(HRP)-conjugated secondary antibodies were obtained
from Cell Signaling Technology (Danvers, MA). Antibo-
dies recognizing acetyl histone was purchased from
Millipore (Billerica, MA) and HDAC6 antibody from
Abcam (Cambridge, MA). Antibody against cyclin B1
was obtained from Santa Cruz Biotechnology (Santa
C r u z ,C A ) .A l e x a4 8 8 ™-conjugated secondary antibody
and phalloidin-Alexa 546™ were obtained from Molecu-
lar Probes/Invitrogen (Carlsbad, CA). Pan caspase inhi-
bitor z-VAD-FMK was purchased from Promega
(Madison, WI).
Cytotoxicity assay
LDH levels were determined using the Non-radioactive
Cytotoxicity Kit (Promega, Madison, WI) according to
manufacturer’s instructions. Cells plated in a 24-well
plate were incubated with different concentrations of
curcumin for various lengths of time as indicated. To
obtain the released LDH, media were collected and cell
debris was removed via brief centrifugation. Viable cell
LDH was collected after re-adding 1ml of fresh serum-
free medium. Cells were lysed by freezing for 15 min-
utes at -70°C followed by thawing at 37°C. The med-
ium was collected and cleared from cell debris using
centrifugation. The relative release of LDH was deter-
mined as the ratio of released LDH versus total LDH
from viable cells. Assays were performed twice in
triplicate.
Immunoblotting
Cell lysates were prepared in a buffer containing 20 mM
Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 0.1% Triton X-100, 2.5 mM sodium pyropho-
sphate, 1 mM b-glycerolphosphate, 1 mM sodium vana-
date, 1 mM phenylmethylsulfonyl fluoride and 5 mg/ml
of antipapain, leupeptin and pepstatin, sonicated and
briefly centrifuged. Protein concentrations of the super-
natants were determined by the DC protein assay (Bio-
Rad, Hercules, CA). Equal amounts of protein were
resolved by SDS-PAGE and transferred to nitrocellulose.
The membranes were blocked in 5% non-fat milk in
tris-buffered saline with 0.1% Tween 20 (TBST) and
then incubated overnight at 4°C with primary antibodies
diluted in 5% bovine serum albumin/TBST. After incu-
bation with HRP-conjugated secondary antibodies in 5%
non-fat milk/TBST, the protein bands were visualized
by Enhanced Chemiluminescence Plus (GE Healthcare,
Piscataway, NJ).
Immunofluorescence
Cells grown on glass coverslips were incubated with cur-
cumin as indicated and fixed with either ice-cold metha-
nol (b-tubulin, acetylated tubulin) or 4%
paraformaldehyde (cleaved caspase-3, HDAC4) with
subsequent permeabilization with saponin (Sigma-
Aldrich). For analysis of mitotic cells, DAOY cells were
synchronized by incubation with 2 mM thymidine for
18 hours. Subsequently, after the block was released for
3 hours, cells were arrested in prometaphase with 100
nM nocodazole for 8 hours. The block was then
released in the presence of DMSO or curcumin as indi-
cated, and the cells were fixed as described above. Pri-
mary antibodies were diluted in PBS with 1% bovine
serum albumin (PBS-BSA) and incubated overnight at 4°
C. Samples were then incubated with Alexa 488™-o r
Alexa 546™-conjugated secondary antibodies and
mounted in Prolong Gold (Invitrogen). DNA was visua-
lized with TO-PRO3 (Invitrogen) after incubation with
RNase A. Images were acquired with a Leica TCS SP5
laser-scanning confocal microscope and LSM software
(Leica Microsystems, Mannheim, Germany).
Cell cycle analysis
DAOY cells were treated with curcumin for indicated
times, harvested, fixed in cold 70% ethanol, and stored
o v e r n i g h ta t- 2 0 ° C .D N Aw a ss t a i n e dw i t h1 0 0m g / m l
propidium iodide (PI) and 20 mg/ml ribonuclease A in
hypotonic citrate buffer. Samples were analyzed on an
Accuri C6 flow cytometer system (Accuri Cytometers,
Ann Arbor, MI) as described [33]. Interference from
curcumin auto-fluoresence was not observed with the
parameters used to acquire the profiles.
HDAC activity assay
HDAC activity was measured with the fluorometric
HDAC Activity Assay Kit (Abcam, Cambridge, MA)
according to manufacturer’s protocols. Briefly, cells were
incubated with increasing concentrations of curcumin
for 3 hours and then lysed with a buffer containing 50
mM HEPES, 150 mM NaCl, and 0.1% Triton X-100
supplemented with protease inhibitors. The cell lysates
were sonicated, cleared, and incubated with assay buffer
containing the HDAC substrate [Boc-Lys(Ac)-AMC] for
30 min at 37°C. The reaction was terminated, and the
fluorescence intensity was measured in a fluorescence
plate reader with Ex. = 350-380 nm and Em. = 440-460
nm.
In vivo studies
Female hairless SCID mice (Charles River Laboratories,
Wilmington, MA), 5-6 weeks old, were injected subcuta-
neously with 7 × 10
6 viable DAOY cells or tdTomato-
expressing DAOY cells with matrigel. Tumors were
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was begun. Corn oil or curcumin dissolved in corn oil
(1 mg/kg body weight) was delivered daily by oral
gavage to each group (8-12 mice per group). The tumor
size was measured twice a week with a caliper, and
tumor volumes were calculated according to the formula
length × width × depth × 0.5. Mice with weight loss of
≥15% of the initial weight or a tumor volume ≥2,000
mm
3 were euthanized. Tumors were harvested, and
tumor lysates were prepared in buffer containing 10
mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% Tri-
ton X-100 supplemented with phosphatase and protease
inhibitors.
Fluorescence signals from tumor xenografts of tdTo-
mato-DAOY cells were acquired once a week with a
Kodak In Vivo Multispectral FX PRO imaging system
(Carestream, Woodbridge, CT) using the following set-
tings: Ex. 550 nm, Em. 600 nm, no binning, f/stop 2.8,
focal plane 13.1 mm, field-of-view 119.1 mm.
Smo/Smo transgenic mice [34] were treated with cur-
cumin or corn oil daily by oral gavage from the point of
weaning (9 mice per group). Treatment was continued
until clinical manifestation of the disease, when animals
were euthanized and tumor tissues were collected for
analysis. Animal experiments were performed according
to the NIH Guide for the Care and Use of Experimental
Animals and approved by our Institutional Animal Care
and Use Committee. All animals were given free access
to water and feed.
Statistical analysis
Data are presented as mean ± SD unless otherwise indi-
cated. Differences between means of the two groups
were analyzed with the use of a two-tailed unpaired Stu-
dent’s t-test or two-way ANOVA test. Survival curves
for Smo/Smo transgenic mice were analyzed using the
non-parametric Kaplan-Meier method. When required,
P values are stated in the figure legends.
Results
Curcumin induces apoptosis in medulloblastoma cells
To investigate the effect of curcumin on medulloblas-
toma, we treated the human medulloblastoma cell line
DAOY with increasing concentrations of curcumin.
After 16 hours, curcumin-treated DAOY cells under-
went morphological changes, such as cell shrinking,
rounding, and detachment (Figure 1A), suggesting that
curcumin might induce cell death. Increasing concentra-
tions of curcumin correlated with an increase in lactate
dehydrogenase (LDH) releasea t2 4h o u r s( F i g u r e1 B ) .
At higher concentrations of curcumin, LDH release was
observed after as early as 8 hours of treatment, suggest-
ing that curcumin induces cell death in a time- and con-
centration-dependent manner in these cells.
Curcumin-treated cells showed increased cleavage of
caspase-3 (Figure 1C) and its downstream substrate poly
(ADP-ribose)polymerase (PARP) (Figures. 1C, D). Both
are hallmarks of dose- and time-dependent apoptotic
cell death when compared with results for vehicle-trea-
ted cells. Furthermore, curcumin-induced apoptosis was
blocked by z-VAD-FMK, a potent inhibitor of caspases
(Additional file 1), suggesting that curcumin induces
caspase-dependent apoptosis in DAOY cells. Increased
PARP cleavage was also observed in two other medullo-
blastoma cell lines, D431 Med and D283 Med (Addi-
tional file 2), indicating that curcumin triggers apoptosis
in medulloblastoma cells.
Curcumin induces cell cycle arrest at G2/M phase
Uncontrolled cell division can lead to programmed cell
death. In carcinoma, it is well documented that curcu-
min can arrest cells either in the G1/S [35] or G2/M
[36] stage of the cell cycle. We tested whether curcumin
affects the cell cycle progression of DAOY cells using
flow cytometry. DNA analysis of curcumin-treated cells
revealed an increase of cells arrested in the G2/M phase
as early as 7 hours after treatment (Figure 2A, B).
Although in DMSO-treated control cells, only 29.9% of
the cells were in G2/M phase, 51.4% and 42.9% of cells
treated with 10 and 20 μM curcumin were found in G2/
M, respectively. The effects of curcumin-induced cell
cycle arrest were more pronounced after 24 hours of
treatment, when 74.5% of curcumin-treated cells were in
the G2/M phase compared with 30.8% of control cells.
Thus, curcumin arrests DAOY cells at G2/M of the cell
cycle. It is well accepted that a prolonged arrest in G2/
M phase leads to apoptotic cell death [37,38]. Interest-
ingly, with higher concentrations of curcumin, DAOY
cells seemed to escape from cell cycle arrest, suggesting
that high concentrations of curcumin could promote
mitotic slippage and subsequent apoptosis.
Curcumin induces acetylation of microtubules and
microtubule-associated mitotic catastrophe
It has been reported previously that curcumin inhibits
microtubule assembly through binding with tubulin
[39]. Thus, we hypothesized that curcumin-induced cell
cycle arrest in G2/M might be due to its effects on
microtubules and abnormal mitotic spindle formation.
In interphase cells, we found a reduced microtubule
density upon curcumin treatment (Figure 3A). However,
the effect of curcumin on microtubules was much more
pronounced in mitotic cells (Figure 3B). DAOY cells
were arrested in prometaphase by a thymidine-nocoda-
zole block and then released in the presence of curcu-
min or vehicle. Sixty minutes after release of the mitotic
block, vehicle-treated cells clearly formed bipolar mitotic
spindles and showed the alignment of compact
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showed segregation of chromosomes toward each pole
(Figure 3B, arrow). Curcumin-treated mitotic cells
exhibited a higher incidence of spindle abnormalities
(64% ± 6%, compared with 11 ± 4% of vehicle control)
and disorganized alignment of chromosomes (Figure 3B,
arrowheads; and Figure 3C). These results suggest that
curcumin preferentially affects the organization of spin-
dle microtubules.
Tubulin acetylation is increased in curcumin-treated
medulloblastoma cells
Post-translational modifications of tubulin are crucial for
regulating microtubule stability and function. Using
modification-specific anti-tubulin antibodies, we found
that in curcumin-treated DAOY cells, acetylated a-
tubulin accumulated in a dose-dependent manner as
early as 3 hours after treatment (Figure 4A). Similarly,
curcumin increased a-tubulin acetylation in D431 Med
and D283 Med cells (Additional file 2), while glutamyla-
tion and tyrosination were not affected in any of the
medulloblastoma cell lines (data not shown). Interest-
ingly, in interphase cells, acetylated a-tubulin was found
predominantly in the perinuclear region of vehicle-trea-
ted cells, where the major population of stable microtu-
bules resides (Figure 4B). In curcumin-treated DAOY
cells, we found increased staining for acetylated a-tubu-
lin throughout the cytoplasm. In addition, in mitotic
DAOY cells, acetylated tubulin was found predomi-
nantly at the mitotic spindles and the intercellular
bridge of cells undergoing cytokinesis (Figure 4C). In
curcumin-treated cells, acetylated a-tubulin at the
Figure 1 Curcumin induces apoptosis in medulloblastoma cells. A. Phase contrast images of DAOY cells incubated with indicated
concentrations of curcumin for 16 hours. Bar, 100 μm. B. LDH release as measure of the cytotoxic effect of curcumin. C. Immunoblot of cleaved
caspase-3 and PARP in curcumin-treated DAOY cells. a-tubulin immunoblot confirms that equal amounts of protein were used in the analysis. D.
Immunofluorescence of control and curcumin-treated DAOY cells (16 hours) for cleaved capase-3 (green) and F-actin (red). Bar, 20 μm.
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curcumin alters the acetylation pattern of microtubules
and their organization at the spindle poles.
Curcumin blocks HDAC activity
The intricate balance between acetylation and deacetyla-
tion of proteins is regulated by the activities of HATs
and HDACs. Using an in vitro activity assay, we found
that increasing concentrations of curcumin blocked
HDAC activity in DAOY cells (Figure 5A, 6 hours). To
test whether curcumin affects a specific HDAC isoform,
we screened the expression profiles of various HDAC
family members upon curcumin treatment by immuno-
blotting. We detected several HDAC isoforms including
HDAC2, 4, 5, and 7 in DAOY cells, but found only
HDAC4 levels to be decreased upon curcumin treat-
ment (Figure 5B), while other family members did not
show any significant change. In addition, overall histone
Figure 2 Curcumin elicits G2/M phase arrest. A. Cell cycle profiles of curcumin-incubated DAOY cells as analyzed by flow cytometry. Cells
were exposed to curcumin at the indicated concentrations for 7 hours (top) and 24 hours (bottom). Note the increase in cells arrested in G2/M
upon curcumin treatment. B. Quantitative analysis of cells in A obtained from three independent experiments. Averages of mean ± SD are
shown.
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treated cells (Figure 4A) suggesting that the observed
reduction in HDAC activity might be due primarily to
loss of HDAC4.
HDAC4 shuttles between the nucleus and cytoplasm,
a process that is regulated by HDAC4 phosphorylation.
While curcumin treatment dramatically reduced
HDAC4 phosphorylation in all three medulloblastoma
cell lines (Figure 5C, Additional file 3), the subcellular
localization of HDAC4 did not change after six hours of
curcumin treatment (Figure 5D, Additional file 4). Con-
sistent with this notion, curcumin did not elicit changes
in acetyl-histone levels in these cells (Figure 4A), sug-
gesting that curcumin targets cytoplasmic HDAC4 and
alters its function on cytoplasmic rather than nuclear
substrates.
Curcumin reduces medulloblastoma tumor growth in vivo
To evaluate the potency of curcumin to inhibit medullo-
blastoma growth in vivo,w eu s e dt w oi n d e p e n d e n t
mouse models: subcutaneous DAOY xenografts and the
Smo/Smo transgenic medulloblastoma model. In Smo/
Smo mice, a constitutively activated form of Smoothened
(Smo) is expressed in CGNPs, resulting in a high tumor
incidence with an early onset of medulloblastoma tumors
[34]. DAOY cells stably expressing tdTomato were
implanted subcutaneously, and curcumin was adminis-
tered daily by oral gavage after tumors were established.
As shown in Figure 6A and Additional file 5, curcumin
suppressed the tumor growth significantly when com-
pared with the control group (1442 ± 225 mm
3 in curcu-
min-treated group vs. 2294 ± 202 mm
3 in control group;
P < 0.001). Fluorescence imaging of tumors established
with tdTomato-DAOY cells confirmed the suppression
of tumor growth by curcumin (Figure 6A, bottom panel).
One inherent problem of drug delivery for brain
tumors is the BBB. Thus, we tested directly the efficacy
of curcumin to inhibit tumor growth in brain tumors.
Smo/Smo transgenic mice, a recently established medul-
loblastoma model, express the active mutant of Smo in
Figure 3 Curcumin affects microtubule dynamics and mitotic
spindle assembly. A. Immunofluorescence for b-tubulin in DAOY
cells treated with DMSO (0 μM) or curcumin (10, 20 μM) for 6 hours.
Bar, 20 μm. B. Analysis of mitotic spindle microtubules in DAOY
cells. Mitotic cells were released from the G2/M arrest in the
presence or absence of curcumin. The cells were fixed after 60 min
of release and stained for b-tubulin (red) and DNA (blue). The arrow
indicates segregation of chromosomes along the mitotic spindle,
while the arrowhead shows abnormal spindle formation and
missegregation of chromosomes. Bar, 20 μm. C. Quantitative analysis
of cells with abnormal mitotic spindles after 60 min of incubation
with either vehicle or 20 μM curcumin. Error bars indicate standard
deviations of three independent experiments.
Figure 4 Curcumin induces tubulin acetylation.A .D A O Yc e l l s
were exposed to increasing concentration of curcumin for 3 hours
and then immunoblotted with antibodies indicated. Increased
acetylation of tubulin was also observed in interphase (B) and
mitotic (C) cells after 16 hours of curcumin treatment. Methanol-
fixed cells were immunostained with antibody specific for
acetylated tubulin (green). DNA stained blue. Bar, 20 μm.
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Page 7 of 13Figure 5 Curcumin blocks HDAC activity. A. Curcumin-treated DAOY cells (6 hours) were lysed and subjected to a fluoremetric HDAC activity
assay as described in Materials and Methods. Data represent the average of the mean ± SEM of two independent experiments done in
triplicates B. C. Expression levels of various HDAC family members (B) and phosphorylation level of HDAC4/5/7 (C) in DAOY cells treated with
curcumin for 3, 15 and 24 hours. Representative immunoblots are shown. GAPDH immunoblots indicate loading of equal amounts of protein.
Numbers below immunoblots in B are the mean of the intensity of three independent experiments, normalized to control cells at each time
point and concentration. D. Subcellular localization of HDAC4 (green) in DAOY cells. Incubation with curcumin (6 hours) did not significantly
affect the cellular distribution of HDAC4. Nuclei are indicated by DNA (blue). Bar, 30 μm.
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Page 8 of 13CGNPs, and tumors form in more than 90% of mice
within two months of age [34]. Curcumin was delivered
orally once daily, and animals were monitored and sacri-
ficed upon manifestation of clinical symptoms. As
shown in Figure 6B, curcumin-treated mice had a signif-
icantly increased survival time when compared with
corn oil-treated control mice, suggesting that curcumin
can cross the BBB and exhibit therapeutic effects in the
brain. Interestingly, the biochemical analysis of medullo-
blastoma tumors collected from each group showed an
increase in apoptotic markers (cleaved caspase-3 and
PARP), decrease in HDAC4 level and phosphorylation,
and elevated acetylation of a-tubulin in curcumin-trea-
ted tumors when compared with control tumors (Figure
6C), mirroring the results obtained in cultured medullo-
blastoma cells.
Figure 6 Curcumin reduces tumor growth in DAOY in vivo tumor xenografts and Smo/Smo mice. A. Effect of curcumin on tumor growth
of subcutaneous xenograft tumors in nude mice. 30 days after cell injection (arrow), each group of mice (N = 12) received corn oil or curcumin
(1 g/kg body weight) once daily and the tumor volume was measured by using a caliper. Data are expressed as mean ± SEM. *, P < 0.05; **, P <
0.01; ***, P < 0.001. Data are representative of three independent studies. Bottom panel, fluorescent ventral images of tumor-bearing mice.
tdTomato-expressing tumors were imaged once a week and representative images are shown. B. Life span of control and curcumin-treated
Smo/Smo (N = 9) plotted as Kaplan-Meier survival curve. The median survival time of curcumin-treated mice was 192 days vs 144 days of
control mice (corn oil). P = 0.0308 (log rank analysis). C. Apoptotic markers, tubulin acetylation and HDAC expression and phosphorylation in
tumor lysates obtained from each group of the Smo/Smo mice.
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In this study, we demonstrate that curcumin induces
apoptosis in medulloblastoma cells and is accompanied
by reduced HDAC4 expression, increased tubulin acety-
lation, and arrest at the G2/M phase of the cell cycle
followed by mitotic catastrophe, and cell death. We also
show anti-tumor effects of curcumin in vivo in tumor
xenografts and a transgenic medulloblastoma tumor
model. Thus, our in vitro and in vivo data suggest that
curcumin has the potential to be developed as a thera-
peutic molecule for medulloblastoma.
Microtubules form the mitotic spindle during cell
division. Because of the rapid assembly and disassem-
bly of microtubules during the alignment and separa-
tion of chromosomes, spindle microtubules are in
general more dynamic than interphase microtubules
[40]. Compounds that inhibit these dynamics lead to
cell cycle arrest in the G2/M phase, eventually result-
ing in cell death. Curcumin has been shown to bind to
tubulin, to induce tubulin aggregation, and to depoly-
merize interphase and mitotic microtubules in HeLa
and MCF-7 cells [39]. Consistent with these data, we
observed reduced microtubule density in interphase
medulloblastoma cells treated with curcumin. In mito-
tic cells, however, we found that while the mitotic
spindle microtubules were disorganized, they displayed
increased staining intensity, suggesting stabilization of
microtubules. In addition, curcumin treatment of
DAOY cells resulted in increased tubulin acetylation.
Although the exact function of post-translational tubu-
lin acetylation is not known, it is usually considered to
be associated with increased microtubule stability [41].
Thus, it is possible that factors other than direct bind-
ing of curcumin to tubulin play a role in the altered
organization of the mitotic spindle in curcumin-treated
medulloblastoma cells.
We found that curcumin is a novel modulator of
HDAC4. In curcumin-treated cells, HDAC activity was
inhibited and HDAC4 expression was reduced, while the
expression levels of other HDAC isoforms did not
appear to be affected. At this point, we do not know
how curcumin regulates HDAC4 expression and HDAC
activity. Studies to determine the molecular mechanisms
continue in our laboratory. Reduced HDAC activity and
HDAC4 levels were observed as early as three hours
upon curcumin-treatment, coinciding with increased a-
tubulin acetylation. Mitotic spindles were altered as
early as 30 min after treatment (data not shown) and
very prominent after 60 min (Figure 3B), indicating a
potential of curcumin as an anti-mitotic drug. At these
early time points, we did not find any indication of cur-
cumin-treated cells undergoing apoptosis, nor did we
find substantial changes in some of the well-known sig-
naling pathways affected by curcumin, such as NFB
(Figure 5B) or Akt (data not shown). Therefore, we sug-
gest that HDAC4 inhibition in curcumin-treated cells
might contribute to the induction of apoptosis rather
than being a byproduct of apoptosis. This is further sup-
ported by our observation that inhibition of caspase-3
did not prevent reduced expression of HDAC4 upon
curcumin treatment (Additional file 1). The effects of
curcumin observed in cell lines were mirrored in in vivo
models of medulloblastoma, namely DAOY xenografts
and the Smo/Smo transgenic mice. In both medulloblas-
toma models, curcumin significantly reduced tumor
growth and increased survival, respectively. Molecular
analysis of curcumin-treated and control tumors
revealed reduced HDAC4 expression and increased
tubulin acetylation, suggesting that curcumin induces
apoptosis by similar mechanisms in culture and in vivo
medulloblastoma.
A disrupted equilibrium as a result of increased
HDAC expression and activity has been associated with
increased proliferation, migration, angiogenesis, differen-
tiation, invasion, and metastasis and enables cancer cells
to evade cell cycle arrest and apoptosis by suppressing
the transcription of cell cycle inhibitors and pro-apopto-
tic factors [14,15,42]. Interestingly, a recent study found
that forced expression of HDAC4 in cerebellar granule
n e u r o n sp r o t e c t st h e s ec e l l sa g a i n s ta p o p t o s i s[ 4 3 ] .W e
show that curcumin targets HDAC4 in medulloblastoma
cells and reduces HDAC activity. Thus, curcumin might
target one of the critical pathways that allow cancer
cells to evade apoptosis. Previous studies reported that
curcumin represses p300/CBP HAT and inhibits acetyla-
tion of p53 [44,45]. However, we did not find changes in
either p300 phosphorylation and histone H3 or p53
acetylation under our experimental conditions (data not
shown), while HDAC4 expression was reduced in three
medulloblastoma cell lines as well as in vivo (Figure 5B
and Additional file 3). Similarly, studies in other experi-
mental systems also found no effects of curcumin on
p300 activity [44] suggesting that p300 inhibition by
curcumin might be cell-type specific. Furthermore, we
did not find significant changes in the levels of other
HDAC isoforms, suggesting that in medulloblastoma
cells HDAC4 is a specific target of curcumin.
In contrast to ubiquitous class I HDACs, HDAC4 as a
class IIa family member is restricted to certain tissues,
including the brain, and can shuttle between the cyto-
plasm and the nucleus. The translocation of HDAC4
from the cytoplasm to the nucleus is regulated by locali-
zation signals and interaction with 14-3-3 proteins
through three conserved phosphorylation sites [46].
However, curcumin treatment did not alter the cytoplas-
mic localization of HDAC4 in DAOY cells, suggesting
that curcumin’s effect on HDAC4 might affect predomi-
nantly non-histone targets rather than chromatin
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study found that Shh signaling, a major signaling path-
way affected in medulloblastoma, is regulated by Gli
acetylation and HDAC1 [47]. Nevertheless, this study
did not find any link between HDAC4 and Shh signaling
in fibroblasts. However, given the cell-type specific
expression pattern of HDAC4 we cannot exclude that
such a link might exist in medulloblastoma cells. In
addition, another study showed that curcumin inhibits
the Shh pathway in medulloblastoma cells [32]. We
found that curcumin was effective in the Smo/Smo
medulloblastoma model, which increased survival, while
HDAC4 expression was reduced at the same time. It
remains to be determined whether HDAC inhibition is a
missing link between curcumin and its effects on Shh
signaling in medulloblastoma.
Although potential chemotherapeutics may show pro-
mise in medulloblastoma culture models, the BBB
remains an obstacle for the development of drugs for
brain tumors. Indeed, about 98% of all small molecule
drugs and all large molecules such as therapeutic anti-
bodies and peptides will be prohibited from crossing
into the brain. We show that orally delivered curcumin
increases survival in Smo/Smo mice and thus, exhibits
chemotherapeutic effects in the brain. Our data are con-
sistent with studies of curcumin in various central ner-
vous system (CNS) disorders including Alzheimer’s
disease that showed a potent effect of orally delivered
curcumin in the brain [9]. In addition, curcumin crossed
the BBB and inhibited tumor growth in orthotopic glio-
blastoma models when administered through the tail
vein [11] or injected i.p. [10]. Bioavailability of curcumin
in the brain is further supported by multiphoton micro-
scopic studies and radiolabel distribution studies in mice
that showed that curcumin administered systemically
can cross the BBB, can be absorbed in the brain, and
exerts biological effects in the brain [7]. These studies
are consistent with our observations that curcumin can
cross the BBB, as manifested in increased survival in
curcumin-treated Smo/Smo mice, and that curcumin is
a valid anti-cancer agent for brain tumors.
Despite advances in treatment, a favorable outcome for
patients with medulloblastoma lags behind many other
pediatric cancers and is often associated with severe
long-term side effects. For example, a small molecule
inhibitor of Shh succeeded in eradicating spontaneous
medulloblastoma in transgenic and transplantation
mouse models [5]. However, while these agents might
have no or limited side effects in adults, in juvenile mice
even transient exposures to a Shh pathway inhibitor
resulted in permanent defects in bone development [6].
In addition, while a first clinical trial was initially success-
ful, the patient developed resistance within a short time
[48,49] impeding its therapeutic potential against
medulloblastoma. Thus, it remains a challenge to identify
safer and effective drugs to treat pediatric brain tumors.
Curcumin has been used as a spice for centuries in Asian
cooking and has demonstrated its safety in phase I and II
clinical trials in adults. No adverse reactions in clinical
trials involving children have been reported so far
[50,51]. Curcumin has potential anti-tumor effects in a
variety of cancers including pediatric cancers such as
osteosarcoma [52], neuroblastoma [53], and acute lym-
phoblastic leukemia [54]. Here, we report that curcumin
induces apoptosis in medulloblastoma cells as well as in
vivo models of medulloblastoma. While curcumin
reduced tumor growth in tumor xenografts and increased
survival in Smo/Smo mice, the tumors were not comple-
tely eradicated. A plethora of studies found that curcu-
min can potentiate the anti-tumor effects of other
chemotherapeutics and irradiation. Thus, in combination
with other modes of therapy, curcumin has the potential
to develop into a therapeutic for medulloblastoma with-
out the severe side effects found in current treatment
regimens.
Conclusions
Recently, curcumin has gained attention as a potent
anti-cancer agent with no discernible side effects in sev-
eral cancers. Our studies show that curcumin induces
apoptosis in medulloblastoma cells, reduces tumor
growth in medulloblastoma tumor xenografts and
increases survival in Smo/Smo mice. Thus, curcumin
has the potential to be developed as a therapeutic for
medulloblastoma without the severe side effects found
in current treatment regimens.
Additional material
Additional file 1: Curcumin-induced HDAC4 reduction and inhibiton
of HDAC activity is not blocked by caspase inhibition. A. DAOY cells
were incubated for 2 hours with 20 μM z-VAD-FMK followed by
curcumin treatment in the presence of inhibitor for an additional 8
hours. Lysates were prepared and immunoblotted for HDAC4, HDAC5,
and cleaved caspase-3. GAPDH served as loading control. B. DAOY cells
were treated with z-VAD-FMK and curcumin as described above and
HDAC activity was measured by a fluoremetric HDAC activity assay. Data
are representative of two independent experiments and the mean ± SD
is shown.
Additional file 2: Curcumin induces apoptosis and tubulin
acetylation in medulloblastoma cell lines. D283 Med and D341 Med
cells were incubated with different concentrations of curcumin for 24
hours, lysed and immunoblotted with cleaved PARP, acetyl tubulin and
GAPDH antibodies, respectively.
Additional file 3: Curcumin reduces the expression and
phosphorylation of HDAC4. HDAC expression profiles in
medulloblastoma cell lines. D283 Med (top panel) and D341 Med
(bottom panel) cells were treated with increasing concentrations of
curcumin for 24 hours and then subjected to immunoblotting with
indicated HDAC antibodies.
Additional file 4: Curcumin does not affect subcellular localization
of HDAC4. DAOY cells were treated with curcumin or DMSO for 3 hours
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Page 11 of 13and then subjected to cytoplasm/nucleus fractionation. Equal amount of
proteins from each fraction was subjected to immunoblotting for
HDAC3, 4, 5 and phospho-HDAC4/5/7.
Additional file 5: Curcumin reduces tumor growth in DAOY in vivo
tumor xenografts. Effect of curcumin on tumor growth of
subcutaneous xenograft tumors in nude mice. 30 days after
subcutaneous injection of DAOY cells (arrow), corn oil or curcumin (1 g/
kg body weight) were given to each group of mice (N = 8) once daily
and the tumor volume was measured by using a caliper. Data are
expressed as mean ± SEM. *, P = 0.0512; **, P = 0.0544; ***, P = 0.0694.
Data are representative of two independent studies.
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